Treatment with atypical antipsychotics: new indications and new populations

被引:115
作者
Glick, ID
Murray, SR
Vasudevan, P
Marder, SR
Hu, RJ
机构
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
关键词
mood disorders; dementia; pervasive developmental disorder; OCD; schizophrenia; atypical antipsychotics;
D O I
10.1016/S0022-3956(01)00020-6
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Atypical antipsychotics have revolutionized the treatment of schizophrenia, becoming the treatment of choice for patients not only during their first episode, but also throughout their life course. Of note, as of 1999 more than 70% of prescriptions for these drugs are being prescribed for conditions other than schizophrenia, such as bipolar disorder and geriatric agitation. While there have been very few controlled trials that have established the efficacy of the atypical antipsychotics for these "off-label" uses, there have been a large number of open trials and case reports. The few controlled trials suggest that the atypical antipsychotics may be useful for affective disorders (both mania and depression), geriatric conditions such as senile dementia and aggression, as well as a variety of other disorders. Atypical agents may be particularly helpful for elderly, child, or adolescent patients who are especially susceptible to the side effects of medications and whose risk of tardive dyskinesia is high but further controlled studies are necessary. (C) 2001 EIsevier Science Ltd. All rights reserved.
引用
收藏
页码:187 / 191
页数:5
相关论文
共 17 条
[1]
Al-Mulhim A, 1998, CAN J PSYCHIAT, V43, P645
[2]
Risperidone may worsen fluoxetine-treated OCD [J].
Andrade, C .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (05) :255-256
[3]
PUBLICATION BIAS AND DISSEMINATION OF CLINICAL RESEARCH [J].
BEGG, CB ;
BERLIN, JA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (02) :107-115
[4]
Olanzapine compared to lithium in mania: a double-blind randomized controlled trial [J].
Berk, M ;
Ichim, L ;
Brook, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (06) :339-343
[5]
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial [J].
Berk, M ;
Brook, S ;
Trandafir, AI .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (03) :177-180
[6]
BUCKLEY PF, 1999, ANN M AM COLL NEUR 1
[7]
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia [J].
De Deyn, PP ;
Rabheru, K ;
Rasmussen, A ;
Bocksberger, JP ;
Dautzenberg, PLJ ;
Eriksson, S ;
Lawlor, BA .
NEUROLOGY, 1999, 53 (05) :946-955
[8]
FINDLING RL, 2000, PSYCHIATRY, V39, P509
[9]
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial [J].
Katz, IR ;
Jeste, DV ;
Mintzer, JE ;
Clyde, C ;
Napolitano, J ;
Brecher, M .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (02) :107-+
[10]
Stuttering: Neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity [J].
Maguire, GA ;
Gottschalk, LA ;
Riley, GD ;
Franklin, DL ;
Bechtel, RJ ;
Ashurst, J .
COMPREHENSIVE PSYCHIATRY, 1999, 40 (04) :308-314